Hypotension News and Research

RSS

Early use of norepinephrine could benefit patients with sepsis and low blood pressure

Patients with septic shock who were treated with norepinephrine earlier than patients receiving standard care were more likely to have their blood pressure and shock stabilized within six hours of diagnosis, according to a randomized, double-blind, controlled trial published online in the American Thoracic Society’s American Journal of Respiratory and Critical Care Medicine.

4 Feb 2019

Study could lead to a potential new way of treating sepsis

Australian emergency doctors are at the forefront of a large clinical study to assess how clinicians are treating sepsis.

11 Dec 2018

Study shows link between disrupted sleep and reduced capability to control posture, balance

Disturbances during sleep decrease capability to control posture and balance according to researchers from the Department of Engineering and Warwick Medical School at the University of Warwick who have an article published today in Scientific Reports.

30 Nov 2018

Researchers identify sepsis symptoms that contribute to patient mortality

Using patient records from 210,289 hospital visits between 2013 and 2016, Drexel University researchers have identified the specific symptoms that put patients at the greatest risk of dying from sepsis - and they're not what many clinicians might think.

26 Nov 2018

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved LORBRENA, a third-generation anaplastic lymphoma kinase tyrosine kinase inhibitor for patients with ALK-positive metastatic non-small cell lung cancer whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

5 Nov 2018

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

AstraZeneca will present 20 abstracts including a late-breaking oral presentation on the full results from the Phase III cardiovascular outcomes trial DECLARE -TIMI 58, the broadest SGLT2 inhibitor CVOT conducted to date, as well as new research from the Company's Cardiovascular, Renal & Metabolism therapy area at the American Heart Association Scientific Sessions, November 10-12, 2018, in Chicago, Illinois, USA.

1 Nov 2018

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced study results on the safety and efficacy of brexpiprazole in the treatment of patients with schizophrenia experiencing severe psychotic symptoms during an acute episode. The data will be presented at the upcoming Psych Congress, held in Orlando from October 25-28, 2018.

26 Oct 2018

Critical illness and major infection can promote brain changes, accelerate cognitive decline

Researchers at Johns Hopkins report that a novel analysis of more than a thousand patients adds to evidence that hospitalization, critical illness and major infection may diminish brain structures that are most commonly affected by Alzheimer's disease.

28 Sep 2018

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

Pfizer Inc. today announced that the U.S. Food and Drug Administration has approved VIZIMPRO [vih-ZIM-pro] (dacomitinib), a kinase inhibitor for the first-line treatment of patients with metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletion or exon 21 L858R substitution mutations as detected by an FDA-approved test.

28 Sep 2018

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

AstraZeneca today announced positive results from the Phase III DECLARE-TIMI 58 cardiovascular outcomes trial for FARXIGA, the broadest SGLT-2 inhibitor CVOT conducted to date.

24 Sep 2018

Epidural stimulation aids in recovery of individuals with spinal cord injury

For the first time since 2009, Stefanie Putnam is able to prepare - and eat - meals for herself, put the vest on her service dog, Kaz, and drive herself to activities with her horse without losing consciousness or gasping for breath.

17 Sep 2018

FDA approves new treatment for people with hairy cell leukemia

AstraZeneca and MedImmune, its global biologics research and development arm, announced today that the US Food and Drug Administration has approved LUMOXITI (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Novel treatment for hairy cell leukemia approved by FDA

The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have received at least two prior systemic therapies, including treatment with a purine nucleoside analog.

14 Sep 2018

Intensive blood pressure control may pose risk for serious falls and fainting, shows study

Kaiser Permanente research published today in the American Journal of Preventive Medicine found if patients with hypertension taking prescribed medications experience unusually low blood pressures -- systolic blood pressure under 110mmHg -- they are twice as likely to experience a fall or faint as patients whose treated blood pressure remains 110mmHg and above.

25 Aug 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018

Dizziness could be an early sign of dementia finds study

A new study has found that people who feel dizzy when they stand up from lying down or sitting positions, are more at risk of developing dementia or stroke. The study was published in the latest issue of the journal Neurology.

25 Jul 2018

Aggressive lowering of blood pressure reduces MCI risk, study shows

Significant reductions in the risk of mild cognitive impairment (MCI), and the combination of MCI and dementia, have been shown for the first time through aggressive lowering of systolic blood pressure in new research results from the federally-funded SPRINT MIND Study reported at the Alzheimer's Association International Conference 2018 in Chicago.

25 Jul 2018

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Merck, known as MSD outside the United States and Canada, announced today that the pivotal Phase 3 KEYNOTE-048 trial investigating KEYTRUDA, Merck's anti-PD-1 therapy, for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma, met a primary endpoint of overall survival as monotherapy in patients whose tumors expressed PD-L1.

25 Jul 2018

Adults with orthostatic hypotension may have undiagnosed cardiovascular disease

Orthostatic hypotension - a rapid drop in blood pressure upon standing up from a sitting or lying down position - is a frequently encountered clinical sign among patients.

3 Jul 2018

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has accepted for standard review a new supplemental Biologics License Application for KEYTRUDA, Merck's anti-PD-1 therapy, as adjuvant therapy in the treatment of patients with resected, high-risk stage III melanoma and granted a Prescription Drug User Fee Act, or target action, date of February 16, 2019.

25 Jun 2018

Hypotension News and Research

Early use of norepinephrine could benefit patients with sepsis and low blood pressure

Study could lead to a potential new way of treating sepsis

Study shows link between disrupted sleep and reduced capability to control posture, balance

Researchers identify sepsis symptoms that contribute to patient mortality

FDA approves LORBRENA for treatment of patients with ALK-positive metastatic NSCLC

AstraZeneca to present Phase III CVOT DECLARE-TIMI 58 results at AHA Scientific Sessions

Study reveals safety, efficacy of brexpiprazole for schizophrenia patients with severe psychotic symptoms

Critical illness and major infection can promote brain changes, accelerate cognitive decline

Pfizer announces FDA approval of VIZIMPRO for first-line treatment of EGFR-mutated metastatic NSCLC

FARXIGA receives positive results in Phase III DECLARE-TIMI 58 cardiovascular outcomes trial

Epidural stimulation aids in recovery of individuals with spinal cord injury

FDA approves new treatment for people with hairy cell leukemia

Novel treatment for hairy cell leukemia approved by FDA

Intensive blood pressure control may pose risk for serious falls and fainting, shows study

CNDA approves KEYTRUDA for treatment of advanced melanoma

Dizziness could be an early sign of dementia finds study

Aggressive lowering of blood pressure reduces MCI risk, study shows

Phase 3 study of KEYTRUDA monotherapy meets primary endpoint

Adults with orthostatic hypotension may have undiagnosed cardiovascular disease

Merck announces FDA acceptance of supplemental Biologics License Application for KEYTRUDA

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News